One Year in, Mastercard’s Checkout Transformation Gains Ground Across Europe
3.6.2025 15:30:00 EEST | Business Wire | Press release
One year after announcing its vision to phase out manual card entry and drive 100% tokenisation, Mastercard is celebrating major strides across Europe, where a growing number of partners are adopting the technologies that underpin safer, smarter digital commerce.
Nearly half of Mastercard e-commerce transactions are now tokenised in Europe. These tokenised transactions, including Secure Card on File (SCOF), Click to Pay, and digital wallets, have increased by over one third in the past year.
Merchant tokenisation, known as Secure Card on File (SCOF), is now live in 45 European countries and territories, helping reduce fraud and improve approval rates by replacing card numbers with dynamic, merchant-specific tokens.
Click to Pay has expanded to 26 European markets, and enrolments have more than doubled over the past year, streamlining checkout for even more returning users.
Meanwhile, payment passkeys are emerging as a breakthrough in digital authentication, allowing users to authenticate with a fingerprint or facial recognition- eliminating passwords.
Newly onboarded partners working with Mastercard to accelerate adoption of seamless, secure digital checkout over the past 12 months include:
- Tokenisation: Checkout.com, Delivery Hero (eFood, Foody, Foodora, and Glovo), Global Collect (Worldline), Monext, Santander
- Click to Pay: Autopay, Consors Finanz BNP Paribas, Fiserv, ICA Banken, Lendable, Nickel, N26, Ogone (Worldline), PayU, SaferPay (Worldline), SIX, and tPay
- Payment passkeys: Dintero, Netopia, Solidgate
“One year into our 100% tokenisation and authentication journey, Europe is gaining strong momentum,” said Brice van de Walle, Executive Vice President, Core Payments Europe, Mastercard. “We’re working with partners to make digital payments more secure and seamless, through Click to Pay, passkeys, and tokens.”
Mastercard research1 shows that 54% of Europeans feel irritated when asked to create an account at checkout, and 82% report some level of frustration navigating friction-heavy processes.
By replacing passwords with passkeys, securely auto filling card details, and using encrypted tokens, Mastercard and its partners are addressing these pain points, making checkout safer and more user-friendly.
“We want to offer the best and most secure payment alternatives to our customers,” said Matias Sanchez, Global Head of Cards and Digital Solutions at Santander. “With tokenisation, their card details are better protected, making checkout easier, faster, and more secure. Partnering with Mastercard allows us to bring this extra layer of safety, therefore Click to Pay is one of our top priorities.”
"Mastercard Payment Passkeys mark a major step toward secure, seamless, and user-friendly digital payments. As the first European processor to combine this with Click to Pay, we’re proud to offer a faster, safer, password-free experience, setting a new standard for digital commerce and building on our strong partnership with Mastercard," said Marius Costin, Chief Executive Officer, NETOPIA Payments.
Mastercard will continue partnering across the region to expand access, raise consumer awareness, and accelerate adoption, advancing its path toward 100% tokenisation and authentication by 2030.
1 Mastercard nationally representative survey of 18,000 consumers aged 18+ across 12 European countries conducted by 3Gem – between 26th November and 3rd December 2024.
*Almost half of Mastercard switched card not present transactions in April 2025 were tokenised.
About Mastercard (NYSE: MA)
Mastercard powers economies and empowers people in 200+ countries and territories worldwide. Together with our customers, we’re building a resilient economy where everyone can prosper. We support a wide range of digital payments choices, making transactions secure, simple, smart and accessible. Our technology and innovation, partnerships and networks combine to deliver a unique set of products and services that help people, businesses and governments realize their greatest potential.
www.mastercard.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250603515548/en/
Contacts
Media
Suman Hughes
suman.hughes@mastercard.com
Gabriel Saltiel
Gabriela.Saltiel@mastercard.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom